NCT01353729View on ClinicalTrials.gov

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 19, 2011

Primary Completion Date

August 2, 2011

Study Completion Date

August 2, 2011

Conditions
Influenza, Human
Interventions
DRUG

600 mg zanamivir + moxifloxacin placebo

zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

DRUG

1200 mg zanamivir + moxifloxacin placebo

zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

DRUG

zanamivir placebo + moxifloxacin placebo

zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose

DRUG

zanamivir placebo + 400 mg moxifloxacin

moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY